NRC Health achieved an 11% year-over-year increase in Total Recurring Contract Value to $151.9 million for Q2 2026, driven by strong go-to-market execution. Despite a GAAP net loss of ($3.3) million, the company posted an Adjusted Net Income of $6.9 million, signaling underlying operational strength for investors.

Key Highlights

  • Adjusted Net Income reached $6.9 million, contrasting with a GAAP net loss of ($3.3) million for the period.
  • Adjusted EBITDA stood at $9.4 million, representing 27% of total revenue.
  • NRC Health announced that TRCV expanded by 11% year over year, arriving at $151.9 million for the quarter that concluded on June 30, 2026, reflecting strong client retention and expansion.

NRC Health announced that TRCV expanded by 11% year over year, arriving at $151.9 million for the quarter that concluded on June 30, 2026, reflecting strong client retention and expansion. The healthcare experience solutions provider posted total revenue of $35.4 million, a 4% increase versus the comparable period a year earlier. While the firm recorded a GAAP net loss of ($3.3) million, it posted Adjusted Net Income of $6.9 million, underscoring the influence of non‑GAAP adjustments on profitability metrics.

Recurring Revenue Momentum

The rise in Total Recurring Contract Value to $151.9 million highlights NRC Health’s capability to both win new contracts and deepen existing relationships within the healthcare sector. Management views this 11% growth as a leading indicator of future performance. Over the three months ending June 30, 2026, total revenue rose 4% to $35.4 million from $34.038 million in the prior year, signaling steady top‑line growth.

CEO Trent Green pointed to effective go‑to‑market execution and ongoing product innovation as primary contributors. The expanding recurring contract base suggests sustained demand for NRC Health’s solutions that aim to improve patient and provider experiences.

Managing Profitability Metrics

For the quarter, GAAP reporting showed a net loss of ($3.3) million, representing roughly 9% of revenue. In contrast, Adjusted Net Income reached $6.9 million, or about 19% of revenue, after excluding items such as earlier‑announced stock‑vesting accelerations and the related cash outlays. Those adjustments included a cash payment of approximately $2.9 million that was reflected in operating cash flow.

Adjusted EBITDA, a non‑GAAP performance gauge, amounted to $9.4 million, or 27% of total revenue. Operating cash flow amounted to $1.4 million, or 4% of revenue, while free cash flow was $0.1 million, illustrating careful liquidity management in light of the one‑off cash expenditures.

Operational Performance and Governance Institute Strength

Quarterly expenses shifted, with direct costs climbing to $13.564 million from $12.974 million a year earlier. Selling, general, and administrative expenses increased to $22.945 million, up from $17.734 million in the prior year, partially driven by severance costs of roughly $270,000 linked to recent restructuring actions led by newly appointed executives. This activity underscores growing demand for NRC Health’s strategic engagements with healthcare leaders and its solutions designed to enhance experience outcomes.

A conference call is scheduled for July 28, 2026 to discuss the results in more detail. With the leadership emphasizing continuous consumer insights and trusted partnerships, investors will watch to see whether strong bookings, especially from The Governance Institute, translate into continued top‑line expansion and a move toward GAAP profitability in upcoming quarters.

Analysis based on the Form 8-K filed 28 July 2026; figures verified against the filing.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.